Functional roles of SPINK1 in cancers
TC Lin - International Journal of Molecular Sciences, 2021 - mdpi.com
Serine Peptidase Inhibitor Kazal Type 1 (SPINK1) is a secreted protein known as a protease
inhibitor of trypsin in the pancreas. However, emerging evidence shows its function in …
inhibitor of trypsin in the pancreas. However, emerging evidence shows its function in …
SPINKs in tumors: potential therapeutic targets
C Liao, Q Wang, J An, M Zhang, J Chen, X Li… - Frontiers in …, 2022 - frontiersin.org
The serine protease inhibitor Kazal type (SPINK) family includes SPINK1-14 and is the
largest branch in the serine protease inhibitor family. SPINKs play an important role in …
largest branch in the serine protease inhibitor family. SPINKs play an important role in …
Serine protease inhibitor kazal type 1, a potential biomarker for the early detection, targeting, and prediction of response to immune checkpoint blockade therapies in …
J Jia, L Ga, Y Liu, Z Yang, Y Wang, X Guo… - Frontiers in …, 2022 - frontiersin.org
Background We aimed to characterize serine protease inhibitor Kazal type 1 (SPINK1) as a
gene signature for the early diagnosis, molecular targeting, and prediction of immune …
gene signature for the early diagnosis, molecular targeting, and prediction of immune …
Gene-expression analysis identifies specific patterns of dysregulated molecular pathways and genetic subgroups of human hepatocellular carcinoma
HG Hass, U Vogel, M Scheurlen, J Jobst - Anticancer research, 2016 - ar.iiarjournals.org
Background. Hepatocellular carcinoma comprises of a group of heterogeneous tumors of
different etiologies. The multistep process of liver carcinogenesis involves various genetic …
different etiologies. The multistep process of liver carcinogenesis involves various genetic …
circRPS16 promotes proliferation and invasion of hepatocellular carcinoma by sponging miR-876-5p to upregulate SPINK1
S Lin, Y Lin, Z Wu, W Xia, C Miao, T Peng… - Frontiers in …, 2021 - frontiersin.org
The roles of serine protease inhibitor Kazal type 1 (SPINK1) in multiple types of cancers
have been significantly documented. However, its specific roles in hepatocellular carcinoma …
have been significantly documented. However, its specific roles in hepatocellular carcinoma …
[HTML][HTML] Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive …
BACKGROUND Insufficient and contradictory data are available about the relation between
direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) development in patients …
direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) development in patients …
SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics
C Yang, L Guo, J Du, Q Zhang, L Zhang - Biomolecules, 2024 - mdpi.com
Low efficacy of treatments and chemoresistance are challenges in addressing refractory
hepatocellular carcinoma (HCC). SPINK1, an oncogenic protein, is frequently …
hepatocellular carcinoma (HCC). SPINK1, an oncogenic protein, is frequently …
Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis.
RR Yan, T Zhu, Q Wang, K Yang, J Li… - Clinical …, 2021 - search.ebscohost.com
Abstract Background: Trypsin Inhibitor Kazal1 (SPINK1) is overexpressed in various tumors,
but its role in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) is unclear. The …
but its role in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) is unclear. The …
Hepatocellular carcinoma before and after the era of direct-acting antiviral therapy for chronic hepatitis C: Dose the story differ?
H Shabana, S Elgamal, A Menessy… - Medical Journal of …, 2024 - mjvh.journals.ekb.eg
Background. Hepatitis C virus (HCV) infection is a leading cause of liver cancer globally.
Treating chronic HCV with direct-acting antivirals (DAAs) in cirrhotic patients has raised …
Treating chronic HCV with direct-acting antivirals (DAAs) in cirrhotic patients has raised …